BTI
VKTX icon

Blue Trust Inc’s Viking Therapeutics VKTX Stock Holding History

Blue Trust Inc’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Hold
482
– – ﹤0.01% 1677
2026
Q1 		$15.7K Sell
482
-330
-41% -$10.6K ﹤0.01% 1714
2025
Q4 		$28.6K Sell
812
-511
-39% -$18.1K ﹤0.01% 1559
2025
Q3 		$34.8K Sell
1,323
-1,153
-47% -$34.4K ﹤0.01% 1524
2025
Q2 		$65.6K Buy
2,476
+529
+27% +$13.9K ﹤0.01% 1245
2025
Q1 		$47K Buy
1,947
+62
+3% +$1.96K ﹤0.01% 1395
2024
Q4 		$75.9K Buy
1,885
+1,478
+363% +$84.3K ﹤0.01% 1052
2024
Q3 		$21.6K Buy
+407
New +$23.9K ﹤0.01% 1914
2023
Q2 		– Sell
-121
Closed -$1K – 2553
2023
Q1 		$1K Hold
121
– – ﹤0.01% 2223
2022
Q4 		$0 Sell
121
-67
-36% -$299 ﹤0.01% 2496
2022
Q3 		$1K Buy
+188
New +$616 ﹤0.01% 2021

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Blue Trust Inc's VKTX Position: Q2 2026 in Review

Blue Trust Inc held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 482 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

Blue Trust Inc first reported a position in VKTX in Q3 2022 and has held it in 11 quarters since. The position peaked at $75.9K in Q4 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Blue Trust Inc held 482 shares of Viking Therapeutics worth $18.8K as of Q2 2026.
  • Blue Trust Inc left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1677 holding.
  • Blue Trust Inc first reported a position in Viking Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • Blue Trust Inc's Viking Therapeutics position peaked at $75.9K in Q4 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.